{"href":"http://player.captivate.fm/services/oembed?url=http%3A%2F%2Fplayer.captivate.fm%2Fepisode%2F175d885a-357d-4e56-8a58-6c2fa62a81ff","version":"1.0","provider_name":"Captivate.FM","provider_url":"https://www.captivate.fm","width":600,"height":200,"type":"rich","html":"<iframe style=\"width: 100%; height: 200px;\" title=\"Potential Role of PROTAC ER Degraders in Therapy for HR-Positive Metastatic Breast Cancer\" frameborder=\"0\" scrolling=\"no\" allow=\"clipboard-write\" seamless src=\"http://player.captivate.fm/episode/175d885a-357d-4e56-8a58-6c2fa62a81ff\"></iframe>","title":"Potential Role of PROTAC ER Degraders in Therapy for HR-Positive Metastatic Breast Cancer","description":"\n        <p>Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville discusses emerging evidence with proteolysis-targeting chimera estrogen receptor degraders for HR-positive metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. </p>\n\n<p>CME information and select publications <a href=\"https://www.researchtopractice.com/OncologyTodayPROTACmBC24\" rel=\"nofollow\">here</a>.</p>\n      ","thumbnail_width":300,"thumbnail_height":300,"thumbnail_url":"https://artwork.captivate.fm/3ac43dd9-771b-40cf-81a8-b9be020a3309/cover.jpg"}